NASDAQ:LPCN Lipocine (LPCN) Stock Price, News & Analysis $3.28 -0.10 (-2.96%) Closing price 06/2/2025 04:00 PM EasternExtended Trading$3.19 -0.09 (-2.87%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Lipocine Stock (NASDAQ:LPCN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Lipocine alerts:Sign Up Key Stats Today's Range$3.12▼$3.5950-Day Range$2.83▼$3.9952-Week Range$2.68▼$11.79Volume50,390 shsAverage Volume35,253 shsMarket Capitalization$17.55 millionP/E RatioN/ADividend YieldN/APrice Target$9.00Consensus RatingStrong Buy Company OverviewLipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.Read More… Lipocine Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreLPCN MarketRank™: Lipocine scored higher than 51% of companies evaluated by MarketBeat, and ranked 564th out of 928 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingStrong Buy Consensus RatingLipocine has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageLipocine has only been the subject of 1 research reports in the past 90 days.Read more about Lipocine's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Lipocine is -4.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lipocine is -4.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLipocine has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Lipocine's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.64% of the float of Lipocine has been sold short.Short Interest Ratio / Days to CoverLipocine has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lipocine has recently increased by 20.40%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLipocine does not currently pay a dividend.Dividend GrowthLipocine does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.64% of the float of Lipocine has been sold short.Short Interest Ratio / Days to CoverLipocine has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lipocine has recently increased by 20.40%, indicating that investor sentiment is decreasing significantly. News and Social Media3.2 / 5News Sentiment0.83 News SentimentLipocine has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Lipocine this week, compared to 1 article on an average week.Search Interest1 people have searched for LPCN on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Lipocine to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lipocine insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.12% of the stock of Lipocine is held by insiders.Percentage Held by InstitutionsOnly 9.11% of the stock of Lipocine is held by institutions.Read more about Lipocine's insider trading history. Receive LPCN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lipocine and its competitors with MarketBeat's FREE daily newsletter. Email Address LPCN Stock News HeadlinesEquities Analysts Set Expectations for Lipocine Q2 EarningsJune 3 at 1:17 AM | americanbankingnews.comLipocine (NASDAQ:LPCN) Receives "Buy" Rating from HC WainwrightMay 30, 2025 | americanbankingnews.comThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Revolution we predicted has arrived." In fact, I believe these robots could impact 65 million Americans lives — by August of this year.June 3, 2025 | Weiss Ratings (Ad)Lipocine (NASDAQ:LPCN) Share Price Crosses Above Fifty Day Moving Average - Here's WhyMay 27, 2025 | americanbankingnews.comLipocine’s LPCN 1148 Gains Fast Track DesignationMay 22, 2025 | tipranks.comLipocine's LPCN 1148 Highlighted in the June 2025 Edition of HepatologyMay 22, 2025 | prnewswire.comLipocine to Present at A.G.P. Healthcare ShowcaseMay 14, 2025 | tipranks.comLipocine to Present at A.G.P.'s Annual Healthcare Company ShowcaseMay 14, 2025 | prnewswire.comSee More Headlines LPCN Stock Analysis - Frequently Asked Questions How have LPCN shares performed this year? Lipocine's stock was trading at $4.88 at the beginning of the year. Since then, LPCN stock has decreased by 32.8% and is now trading at $3.28. View the best growth stocks for 2025 here. How were Lipocine's earnings last quarter? Lipocine Inc. (NASDAQ:LPCN) posted its earnings results on Thursday, May, 8th. The specialty pharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.35). The specialty pharmaceutical company earned $0.09 million during the quarter, compared to analysts' expectations of $0.35 million. When did Lipocine's stock split? Lipocine shares reverse split before market open on Friday, May 12th 2023. The 1-17 reverse split was announced on Friday, May 12th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. How do I buy shares of Lipocine? Shares of LPCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lipocine own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lipocine investors own include Zomedica (ZOM), Plug Power (PLUG), Workhorse Group (WKHS), Ovid Therapeutics (OVID), FuelCell Energy (FCEL), Fortress Biotech (FBIO) and KALA BIO (KALA). Company Calendar Last Earnings5/08/2025Today6/02/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LPCN CIK1535955 Webwww.lipocine.com Phone(801) 994-7383Fax801-994-7388Employees10Year Founded1997Price Target and Rating Average Stock Price Target$9.00 High Stock Price Target$10.00 Low Stock Price Target$8.00 Potential Upside/Downside+174.4%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$16.35 million Net MarginsN/A Pretax Margin-51.17% Return on Equity-19.17% Return on Assets-17.60% Debt Debt-to-Equity RatioN/A Current Ratio12.97 Quick Ratio12.97 Sales & Book Value Annual Sales$3.67 million Price / Sales4.78 Cash FlowN/A Price / Cash FlowN/A Book Value$3.83 per share Price / Book0.86Miscellaneous Outstanding Shares5,350,000Free Float5,021,000Market Cap$17.55 million OptionableNo Data Beta1.52 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:LPCN) was last updated on 6/3/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Social Security Changes No One’s Talking AboutWhile most Americans worry about their next Social Security check... something far bigger is happening behind ...Altimetry | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lipocine Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lipocine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.